ArticleBMC ophthalmology2026
Efficacy and safety of 577 nm subthreshold laser treatment in acute central serous chorioretinopathy.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the subthreshold micropulse laser (SML) treatment in patients with acute central serous chorioretinopathy (CSC). MATERIALS AND
methodsThis retrospective study included 46 eyes from 46 patients with acute CSC. Twenty-five patients were treated with SML, while 21 were observed without intervention. Outcomes evaluated included best corrected visual acuity (BCVA), outer nuclear layer thickness (ONLT), subfoveal choroidal thickness (SFCT), and subretinal fluid (SRF) height. SML was applied using a 577 nm yellow wavelength laser.
resultsIn the SML group, BCVA improved significantly from 0.33 ± 0.13 LogMAR at baseline to 0.07 ± 0.05 LogMAR at 6 months (p < 0.001). The observation group showed improvement from 0.29 ± 0.13 LogMAR to 0.14 ± 0.16 LogMAR (p = 0.011). SFCT decreased significantly in the SML group (460.36 ± 67.91 μm at baseline to 407.44 ± 60.18 μm at 6 months, p = 0.013), with no significant change in the observation group. The SML group also showed a significant increase in ONLT (p < 0.001), and complete SRF resorption was achieved in all patients, compared to 23.8% in the observation group.
conclusionSML treatment is a safe and effective option for managing acute CSC. TRIAL REGISTRATION NUMBER: 2024/010.99/2/21-27.03.2024, retrospective design.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.